INVE.B

365.55

+3.35%↑

HEXA.B

92.6

+2.91%↑

HMS

432.4

+4.6%↑

BILL

74.55

+1.15%↑

ANOD.B

66.4

+1.53%↑

INVE.B

365.55

+3.35%↑

HEXA.B

92.6

+2.91%↑

HMS

432.4

+4.6%↑

BILL

74.55

+1.15%↑

ANOD.B

66.4

+1.53%↑

INVE.B

365.55

+3.35%↑

HEXA.B

92.6

+2.91%↑

HMS

432.4

+4.6%↑

BILL

74.55

+1.15%↑

ANOD.B

66.4

+1.53%↑

INVE.B

365.55

+3.35%↑

HEXA.B

92.6

+2.91%↑

HMS

432.4

+4.6%↑

BILL

74.55

+1.15%↑

ANOD.B

66.4

+1.53%↑

INVE.B

365.55

+3.35%↑

HEXA.B

92.6

+2.91%↑

HMS

432.4

+4.6%↑

BILL

74.55

+1.15%↑

ANOD.B

66.4

+1.53%↑

Search

AddLife AB

Ouvert

143.3 4.37

Résumé

Variation du prix de l'action

24h

Actuel

Min

135.8

Max

144.6

Chiffres clés

By Trading Economics

Revenu

179M

260M

Ventes

304M

2.7B

P/E

Moyenne du Secteur

30.218

74.348

BPA

1.15

Rendement du dividende

1.1

Marge bénéficiaire

9.513

Employés

2,295

EBITDA

238M

602M

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.10%

2.51%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

317M

17B

Ouverture précédente

138.93

Clôture précédente

143.3

AddLife AB Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 mars 2026, 23:31 UTC

Actions en Tendance

Stocks to Watch: Nike, RH, NCino

31 mars 2026, 22:35 UTC

Résultats

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 avr. 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mars 2026, 23:50 UTC

Acquisitions, Fusions, Rachats

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mars 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mars 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mars 2026, 23:21 UTC

Résultats

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mars 2026, 23:14 UTC

Market Talk
Résultats

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mars 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss Widens >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mars 2026, 21:46 UTC

Acquisitions, Fusions, Rachats

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mars 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mars 2026, 21:35 UTC

Résultats

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mars 2026, 21:33 UTC

Résultats

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mars 2026, 21:32 UTC

Résultats

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mars 2026, 21:28 UTC

Résultats

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mars 2026, 21:26 UTC

Résultats

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mars 2026, 21:25 UTC

Résultats

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mars 2026, 21:24 UTC

Market Talk
Résultats

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mars 2026, 21:22 UTC

Résultats

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mars 2026, 21:22 UTC

Résultats

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mars 2026, 21:21 UTC

Résultats

Nike's Digital Channel Still Too Promotional, CFO Says

31 mars 2026, 21:20 UTC

Résultats

Nike CEO: Converse Remains Important to Portfolio

Comparaison

Variation de prix

AddLife AB prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos AddLife AB

AddLife AB (publ), together with its subsidiaries, provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates through Labtech and Medtech segments. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for plastic consumables, cell biology, reagents, lab, and other instruments. The Medtech segment provides medical device products for surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ear, nose and throat, ostomies, and home healthcare, as well as assistive technology for senior citizens and disabled children. It operates in Sweden, the United Kingdom, Ireland, Spain, Denmark, Norway, Italy, Finland, Switzerland, Germany, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
help-icon Live chat